Prostatectomy Clinical Trials

Clinical trials related to Prostatectomy Procedure

Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer. No investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient is an adult biological male.

• Patient has morphologically confirmed and untreated prostate cancer.

• Patient who will be treated with open, laparoscopic or robot-assisted laparoscopic radical prostatectomy.

• Patient is informed about this observational study and has signed the informed consent form.

Locations
Other Locations
Lithuania
Lithuanian University of Health Sciences Hospital Kaunas Clinics, Department of Urology
RECRUITING
Kaunas
Contact Information
Primary
Gustas Sasnauskas, MD
gustas.sas@gmail.com
+37063605330
Time Frame
Start Date: 2024-01-22
Estimated Completion Date: 2039-07
Participants
Target number of participants: 500
Treatments
Non-persistent PSA group
Patients after radical prostatectomy with first postoperative prostate-specific antigen value of \<0.1 ng/ml 4-8 weeks after radical prostatectomy.
Persistent PSA group
Patients after radical prostatectomy with first postoperative prostate-specific antigen value of ≥0.1 ng/ml 4-8 weeks after radical prostatectomy.
Related Therapeutic Areas
Sponsors
Leads: Lithuanian University of Health Sciences

This content was sourced from clinicaltrials.gov